Arcus Biosciences/$RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
$RCUS
Sector
Primary listing
NYSE
Industry
Biotechnology
Headquarters
Employees
627
ISIN
US03969F1093
Website
RCUS Metrics
BasicAdvanced
$1B
-
-$4.20
0.83
-
Price and volume
Market cap
$1B
Beta
0.83
52-week high
$18.75
52-week low
$6.50
Average daily volume
1.1M
Financial strength
Current ratio
5.37
Quick ratio
5.302
Long term debt to equity
12.994
Total debt to equity
15.254
Interest coverage (TTM)
-109.00%
Profitability
EBITDA (TTM)
-426
Gross margin (TTM)
-226.95%
Net profit margin (TTM)
-277.30%
Operating margin (TTM)
-309.22%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-22.25%
Return on equity (TTM)
-63.17%
Valuation
Price to revenue (TTM)
6.302
Price to book
1.9
Price to tangible book (TTM)
1.9
Price to free cash flow (TTM)
-2.933
Free cash flow yield (TTM)
-34.10%
Free cash flow per share (TTM)
-325.28%
Growth
Revenue change (TTM)
-40.51%
Earnings per share change (TTM)
40.46%
3-year revenue growth (CAGR)
-28.85%
3-year earnings per share growth (CAGR)
76.65%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
Bulls say / Bears say
Arcus Biosciences' HIF-2α inhibitor, casdatifan, demonstrated promising results in combination with cabozantinib for renal cell carcinoma, with over 30% confirmed response rates and a median progression-free survival of 9.7 months in the 50mg cohort. (stocktitan.net)
The company maintains a strong financial position, ending Q1 2025 with $1.0 billion in cash, providing ample runway for ongoing and future clinical trials. (stocktitan.net)
Analysts have set a consensus price target of $30.25 for Arcus Biosciences, indicating potential upside from current trading levels. (etfdailynews.com)
Arcus Biosciences reported a Q1 2025 net loss of $112 million, a significant increase from the $4 million loss in Q1 2024, raising concerns about escalating operational expenses. (stocktitan.net)
The company's Q1 2025 revenues declined to $28 million from $145 million in the same quarter the previous year, indicating potential challenges in revenue generation. (nasdaq.com)
AllianceBernstein L.P. sold 1,228,444 shares of Arcus Biosciences, suggesting reduced confidence from institutional investors. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
RCUS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $1B as of July 11, 2025.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of July 11, 2025.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.